CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Tocilizumab InjectionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug733 Deferoxamine Wiki 0.50
drug1978 Questionnaire Wiki 0.15

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D002386 Cataract NIH 0.71
D011014 Pneumonia NIH 0.04

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0000518 Cataract HPO 0.71
HP:0002090 Pneumonia HPO 0.04

There are 2 clinical trials

Clinical Trials


1 Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia

This study project includes a single-arm phase 2 study and a parallel observational cohort study, enrolling patients with COVID-19 pneumonia.

NCT04317092 COVID-19 Pneumonia Drug: Tocilizumab Injection
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: 1-month mortality is defined as the ratio of patients who will alive after 1month from study start out of those registered at baseline

Measure: One-month mortality rate

Time: up to 1 month

Secondary Outcomes

Description: IL-6 levels will be assessed using commercial ELISA method.

Measure: Interleukin-6 level

Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month

Description: Lymphocyte count assessed by routinely used determination of blood count

Measure: Lymphocyte count

Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month

Description: CRP is assessed by routinely used determination of CRP

Measure: CRP (C-reactive protein) level

Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month

Description: calculated from arterial blood gas analyses (values from 300 to 100)

Measure: PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)

Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month

Description: It evaluates 6 variables, each representing an organ system (one for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems), and scored from 0 (normal) to 4 (high degree of dysfunction/failure). Thus, the maximum score may range from 0 to 24.

Measure: Change of the SOFA (Sequential Organ Failure Assessment)

Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month

Description: graded according to CTCAE citeria (v5.0)

Measure: Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0

Time: during treatment and up to 30 days after the last treatment dose

Description: Thoracic CT scan or Chest XR

Measure: Radiological response

Time: at baseline (optional), after seven days and if clinically indicated (up to 1 month)

Description: Days of hospitalization

Measure: Duration of hospitalization

Time: from baseline up to patient's discharge (up to 1 month)

Description: time to invasive mechanical ventilation (if not previously initiated) calculated from baseline to intubation

Measure: Remission of respiratory symptoms

Time: up to 1 month

Description: time to definitive extubation calculated from intubation (any time occurred) to extubation in days

Measure: Remission of respiratory symptoms

Time: up to 1 month

Description: time to independence from non-invasive mechanical ventilation calculated in days

Measure: Remission of respiratory symptoms

Time: up to 1 month

Description: time to independence from oxygen therapy in days

Measure: Remission of respiratory symptoms

Time: up to 1 month

2 Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia. Multicentric, Comparative, Randomized Study

Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, associated with standards treatments in COVID-19 (+) patients, Hospitalized In Intensive care in Tunisia. Multicentric, comparative, randomized study.

NCT04361032 COVID19 Intensive Care Unit Drug: Tocilizumab Injection Drug: Deferoxamine

Primary Outcomes

Description: Evaluate the mortality rate at 90 days. Evaluate the Intensive Care Unit (ICU) and Hospital Mortality rate at day 90 with date and cause of death (if applicable)

Measure: the mortality rate

Time: 90 day


Related HPO nodes (Using clinical trials)